PMID: 11926436Apr 3, 2002Paper

Economic evaluation of linezolid, flucloxacillin and vancomycin in the empirical treatment of cellulitis in UK hospitals: a decision analytical model

The Journal of Hospital Infection
Angela G VinkenD Nathwani

Abstract

Standard antibiotic treatment of infections has become more difficult and costly due to treatment failure associated with the rise in bacterial resistance. New antibiotics that can overcome such resistant pathogens have the potential for great clinical and economic impact. Linezolid is a new antibiotic that is effective in the treatment of both antibiotic-susceptible and antibiotic-resistant Gram-positive bacterial infections, including those resistant to other available antibiotics. This breadth of activity is unique in existing antibiotics for Gram-positive bacteria and serves as the rationale for exploring the hypothesis that linezolid is an appropriate choice when considering empirical treatment of cellulitis in complicated or compromised patients in the nosocomial setting. A decision-modelling approach was used to compare the predicted first-line treatment efficacy and direct medical costs of linezolid with standard treatment of cellulitis among hospitalized patients. For the purposes of this analysis, standard care is defined along two main pathways: (1) initiating care with intravenous (iv) flucloxacillin, switching to vancomycin if the pathogen is found to be resistant to flucloxacillin, or maintaining flucloxacillin if...Continue Reading

References

Nov 1, 1991·Annals of Internal Medicine·A W Karchmer
Jun 1, 1990·Antimicrobial Agents and Chemotherapy·P M Small, H F Chambers
Sep 1, 1984·American Journal of Public Health·A FinkR H Brook
Aug 5, 1995·BMJ : British Medical Journal·J Jones, D Hunter
Sep 1, 1994·The Journal of Infection·R S DykhuizenC C Smith
Jan 1, 1995·The British Journal of Ophthalmology·D KentE W Davies
Jan 1, 1996·Infection Control and Hospital Epidemiology : the Official Journal of the Society of Hospital Epidemiologists of America·A AsensioM Martinez-Ferrer
May 1, 1997·The Journal of Antimicrobial Chemotherapy·F Baquero
Dec 30, 1998·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·A D TiceM J Strauss
Jun 11, 1999·BMJ : British Medical Journal·A DupuyS Bastuji-Garin
Jul 8, 1999·Infection Control and Hospital Epidemiology : the Official Journal of the Society of Hospital Epidemiologists of America·M A Abramson, D J Sexton
Oct 19, 1999·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·C GonzálezJ J Picazo
Mar 10, 2001·Infection Control and Hospital Epidemiology : the Official Journal of the Society of Hospital Epidemiologists of America·T KimA E Simor

❮ Previous
Next ❯

Citations

Sep 21, 2007·Current Infectious Disease Reports·Gary E Stein
Apr 26, 2008·The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care·Dirk SchürmannAnsgar Resch
Dec 19, 2014·Chemical Biology & Drug Design·Talitha I Verhoef, Stephen Morris
Apr 2, 2008·Expert Opinion on Pharmacotherapy·Santiago Grau, Carlos Rubio-Terrés
Jun 16, 2005·Expert Review of Anti-infective Therapy·Matteo BassettiDante Bassetti
Jul 22, 2005·Journal of Advanced Nursing·Joyann AndrewsRoger Watson
Oct 20, 2005·Ophthalmic Plastic and Reconstructive Surgery·Brett S KotlusIra J Udell
Dec 13, 2005·Pharmacy World & Science : PWS·Santiago GrauEsther Salas
Dec 21, 2012·Expert Review of Pharmacoeconomics & Outcomes Research·Mark Bounthavong, Donald I Hsu

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antimicrobial Resistance

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Antimicrobial Resistance (ASM)

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Cellulitis

Cellulitis (erysipelas) is a recurring and debilitating bacterial infection of the skin and underlying tissue. Discover the latest research on cellulitis here.